These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20639253)

  • 1. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response.
    Broering R; Zhang X; Kottilil S; Trippler M; Jiang M; Lu M; Gerken G; Schlaak JF
    Gut; 2010 Aug; 59(8):1111-9. PubMed ID: 20639253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.
    Chen L; Sun J; Meng L; Heathcote J; Edwards AM; McGilvray ID
    J Gen Virol; 2010 Feb; 91(Pt 2):382-8. PubMed ID: 19846672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
    Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
    Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-stimulated gene 15: a dual activity during hepatitis C virus infection.
    Estrabaud E; Asselah T
    Gut; 2010 Aug; 59(8):1017-9. PubMed ID: 20639247
    [No Abstract]   [Full Text] [Related]  

  • 5. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular tools for the treatment of hepatitis C.
    Pawlotsky JM; Gretch DR
    Antivir Ther; 1998; 3(Suppl 3):45-55. PubMed ID: 10726055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.
    Zhu H; Zhao H; Collins CD; Eckenrode SE; Run Q; McIndoe RA; Crawford JM; Nelson DR; She JX; Liu C
    Hepatology; 2003 May; 37(5):1180-8. PubMed ID: 12717400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
    Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
    J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis C: therapeutic perspectives].
    Trépo C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells.
    Chang KO; George DW
    J Virol; 2007 Sep; 81(18):9633-40. PubMed ID: 17609266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3.
    Yasmeen A; Hamid S; Granath FN; Lindström H; Elliott RM; Siddiqui AA; Persson MA
    J Viral Hepat; 2006 Feb; 13(2):87-95. PubMed ID: 16436126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
    Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
    Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.